Intech Investment Management LLC Sells 822 Shares of DexCom, Inc. (NASDAQ:DXCM)

Intech Investment Management LLC trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,743 shares of the medical device company’s stock after selling 822 shares during the quarter. Intech Investment Management LLC’s holdings in DexCom were worth $2,012,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Gilbert & Cook Inc. increased its stake in DexCom by 8.2% in the 4th quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock worth $426,000 after buying an additional 261 shares during the period. 9258 Wealth Management LLC bought a new stake in shares of DexCom during the fourth quarter valued at approximately $286,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of DexCom during the fourth quarter valued at approximately $284,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of DexCom by 156.7% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 67,932 shares of the medical device company’s stock valued at $8,430,000 after purchasing an additional 41,469 shares during the period. Finally, SageView Advisory Group LLC bought a new position in DexCom in the fourth quarter worth approximately $344,000. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,483 shares of company stock valued at $201,708. Company insiders own 0.30% of the company’s stock.

DexCom Trading Down 1.0 %

Shares of NASDAQ:DXCM opened at $69.70 on Tuesday. The business has a 50-day moving average price of $77.32 and a 200-day moving average price of $108.93. The stock has a market cap of $27.72 billion, a price-to-earnings ratio of 44.97, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 EPS. Equities analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Oppenheimer dropped their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Baird R W downgraded shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. Finally, Redburn Atlantic started coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price objective on the stock. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.